Kindlin-2 regulates hemostasis by controlling endothelial cell-surface expression of ADP/AMP catabolic enzymes via a clathrin-dependent mechanism

Blood

Volumn 122, Issue 14, 2013, Pages 2491-2499

  Pluskota, Elzbieta ^a   Ma, Yi ^a   Bledzka, Kamila M ^a   Bialkowska, Katarzyna ^a   Soloviev, Dmitry A ^a   Szpak, Dorota ^a   Podrez, Eugene A ^a   Fox, Paul L ^a   Hazen, Stanley L ^a   Dowling, James J ^b   Ma, Yan Qing ^c   Plow, Edward F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ALKALINE PHOSPHATASE; APYRASE; BREFELDIN A; CD39 ANTIGEN; CHLORPROMAZINE; CLATHRIN HEAVY CHAIN; CYTOSKELETON PROTEIN; ECTO 5' NUCLEOTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; HEMOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; KINDLIN 2; LEVAMISOLE; METHYLAMINE; PADGEM PROTEIN; PHOSPHATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAB PROTEIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; 5' NUCLEOTIDASE; CLATHRIN; KINDLIN 2 PROTEIN, MOUSE; KINDLIN-2 PROTEIN, MOUSE; LEUKOCYTE ANTIGEN; MUSCLE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BLEEDING TIME; BLOOD CLOTTING; CAROTID ARTERY OBSTRUCTION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; ENDOCYTOSIS; ENDOTHELIUM CELL; ENZYME DEGRADATION; ENZYME MECHANISM; FEMALE; HEMOSTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; WILD TYPE; ANIMAL; BIOSYNTHESIS; CELL MEMBRANE; FLOW CYTOMETRY; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; PROTEIN TRANSPORT; SURFACE PLASMON RESONANCE; THROMBOCYTE;

5'-NUCLEOTIDASE; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ANIMALS; ANTIGENS, CD; APYRASE; BLOOD PLATELETS; CELL MEMBRANE; CLATHRIN; CYTOSKELETAL PROTEINS; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HEMOSTASIS; IMMUNOPRECIPITATION; MALE; MICE; MICE, KNOCKOUT; MUSCLE PROTEINS; PLATELET AGGREGATION; PROTEIN TRANSPORT; SURFACE PLASMON RESONANCE;

EID: 84887629722     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-497669     Document Type: Article

References (46)

1. Moser M, Legate KR, Zent R, Fässler R. The tail of integrins, talin, and kindlins. Science. 2009; 324(5929):895-899.
2. Larjava H, Plow EF, Wu C. Kindlins: essential regulators of integrin signalling and cellmatrix adhesion. EMBO Rep. 2008;9(12): 1203-1208.
3. Plow EF, Qin J, Byzova T. Kindling the flame of integrin activation and function with kindlins. Curr Opin Hematol. 2009;16(5):323-328.
4. Meves A, Stremmel C, Gottschalk K, Fässler R. The Kindlin protein family: new members to the club of focal adhesion proteins. Trends Cell Biol. 2009;19(10):504-513.
5. Malinin NL, Plow EF, Byzova TV. Kindlins in FERM adhesion. Blood. 2010;115(20): 4011-4017.
6. Bialkowska K, Ma YQ, Bledzka K, et al. The integrin co-activator Kindlin-3 is expressed and functional in a non-hematopoietic cell, the endothelial cell. J Biol Chem. 2010;285(24): 18640-18649.
7. Ussar S, Moser M, Widmaier M, et al. Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. PLoS Genet. 2008;4(12):e1000289.
8. Malinin NL, Zhang L, Choi J, et al. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nat Med. 2009; 15(3):313-318.
9. Svensson L, Howarth K, McDowall A, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med. 2009;15(3):306-312.
10. Dowling JJ, Gibbs E, Russell M, et al. Kindlin-2 is an essential component of intercalated discs and is required for vertebrate cardiac structure and function. Circ Res. 2008;102(4):423-431.
11. Montanez E, Ussar S, Schifferer M, et al. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev. 2008;22(10):1325-1330.
12. Ma YQ, Qin J, Wu C, Plow EF. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J Cell Biol. 2008; 181(3):439-446.
13. Pluskota E, Dowling JJ, Gordon N, et al. The integrin coactivator kindlin-2 plays a critical role in angiogenesis in mice and zebrafish. Blood. 2011; 117(18):4978-4987.
14. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fässler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 2008;14(3):325-330.
15. Dowling JJ, Vreede AP, Kim S, Golden J, Feldman EL. Kindlin-2 is required for myocyte elongation and is essential for myogenesis. BMC Cell Biol. 2008;9:36.
16. Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13(9): 1086-1095.
17. Zhuo Y, Ilangovan U, Schirf V, et al. Dynamic interactions between clathrin and locally structured elements in a disordered protein mediate clathrin lattice assembly. J Mol Biol. 2010;404(2):274-290.
18. Bledzka K, Liu J, Xu Z, et al. Spatial coordination of kindlin-2 with talin head domain in interaction with integrin β cytoplasmic tails. J Biol Chem. 2012;287(29):24585-24594.
19. Robson SC. Thromboregulation by endothelial cells: significance for occlusive vascular diseases. Arterioscler Thromb Vasc Biol. 2001;21(7): 1251-1252.
20. Marguerie GA, Plow EF. The fibrinogendependent pathway of platelet aggregation. Ann N Y Acad Sci. 1983;408:556-566.
21. Schäfer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol. 2008;6(1):52-60.
22. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost. 2005;31(2):234-246.
23. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signal. 2006;2(2):351-360.
24. Wang LH, Rothberg KG, Anderson RG. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol. 1993;123(5): 1107-1117.
25. Robinson MS, Kreis TE. Recruitment of coat proteins onto Golgi membranes in intact and permeabilized cells: effects of brefeldin A and G protein activators. Cell. 1992;69(1):129-138.
26. McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 2011;12(8): 517-533.
27. Mousavi SA, Malerød L, Berg T, Kjeken R. Clathrin-dependent endocytosis. Biochem J. 2004;377(Pt 1):1-16.
28. Dwyer KM, Robson SC, Nandurkar HH, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest. 2004;113(10):1440-1446.
29. Crikis S, Lu B, Murray-Segal LM, et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant. 2010;10(12):2586-2595.
30. Furukoji E, Matsumoto M, Yamashita A, et al. Adenovirus-mediated transfer of human placental ectonucleoside triphosphate diphosphohydrolase to vascular smooth muscle cells suppresses platelet aggregation in vitro and arterial thrombus formation in vivo. Circulation. 2005;111(6):808-815.
31. Enjyoji K, Sévigny J, Lin Y, et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med. 1999;5(9):1010-1017.
32. Koszalka P, Ozüyaman B, Huo Y, et al. Targeted disruption of cd73/ecto-5′-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res. 2004;95(8): 814-821.
33. Li Z, Zhang G, Liu J, et al. An important role of the SRC family kinase Lyn in stimulating platelet granule secretion. J Biol Chem. 2010;285(17): 12559-12570.
34. Subramaniam M, Frenette PS, Saffaripour S, Johnson RC, Hynes RO, Wagner DD. Defects in hemostasis in P-selectin-deficient mice. Blood. 1996;87(4):1238-1242.
35. Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271-281.
36. Bugge TH, Xiao Q, Kombrinck KW, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci U S A. 1996; 93(13):6258-6263.
37. Papanikolaou A, Papafotika A, Murphy C, et al. Cholesterol-dependent lipid assemblies regulate the activity of the ecto-nucleotidase CD39. J Biol Chem. 2005;280(28):26406-26414.
38. Makiya R, Thornell LE, Stigbrand T. Placental alkaline phosphatase, a GPI-anchored protein, is clustered in clathrin-coated vesicles. Biochem Biophys Res Commun. 1992;183(2):803-808.
39. Abrami L, Liu S, Cosson P, Leppla SH, van der Goot FG. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol. 2003;160(3):321-328.
40. Sandvig K, Olsnes S, Brown JE, Petersen OW, van Deurs B. Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1. J Cell Biol. 1989;108(4):1331-1343.
41. Le Roy C, Wrana JL. Clathrin- and non-clathrinmediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005;6(2):112-126.
42. Liu J, Fukuda K, Xu Z, et al. Structural basis of phosphoinositide binding to kindlin-2 protein pleckstrin homology domain in regulating integrin activation. J Biol Chem. 2011;286(50): 43334-43342.
43. Qu H, Tu Y, Shi X, et al. Kindlin-2 regulates podocyte adhesion and fibronectin matrix deposition through interactions with phosphoinositides and integrins. J Cell Sci. 2011; 124(Pt 6):879-891.
44. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999; 103(2):229-238.
45. Pinsky DJ, Broekman MJ, Peschon JJ, et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest. 2002;109(8):1031-1040.
46. Gayle RB III, Maliszewski CR, Gimpel SD, et al. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. J Clin Invest. 1998; 101(9):1851-1859.